Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
For treating Leishmania major infection in BALB/c mice, we used thalidomide in conjunction with glucan-time. Groups of mice were challenged with 5 × 103 metacyclic promastigotes of L. majorsubcutaneously. A weekafter the challenge, drug treatment was started and continued for 12 days. Thalidomide was orally administrated 30mg/kg/day and glucantime was administrated intraperitoneally (200 mg/kg/day). It was shown that the combined ther-apy is more effective than single therapies with each one of the drugs since the foot pad swelling in the group of micereceived thalidomide and glucantime was significantly decreased (0.9 ± 0.2 mm) compared to mice treated with eitherglucantime, thalidomide, or carrier alone (1.2 ± 0.25, 1.4 ± 0.3, and 1.7 ± 0.27 mm, respectively). Cytokine studyshowed that the effect of thalidomide was not dependent on IL-12; however, it up-regulated IFN-γand down-regulatedIL-10 production. Conclusively, thalidomide seems promising as a conjunctive therapy with antimony in murine modelof visceral leishmaniasis.
참고문헌 (21)
- "Adjuvant Effect of Leishmania majorpromastigotes on the immune response of mice to ovalbumin", 6, pp.123~128 (2002)
- "Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in Thalidomide-treated mice.", 37, pp.485~492 (2004)
- "Experimental Leishmania majorinfection in mice: role of IL-10", 21, pp.211~218 (1999)
- "Dissociation of disease susceptibility inflammation andcytokine profile in lmr1", 2 congenic mice infected withLeishmania major, 2004, pp.5, 188~196
- "Thalidomide.", 363, pp.1802~1811 (2004)
- "Thalidomide and tuberculosis", 6, pp.569~572 (2002)
- "Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis", 71, pp.561~567 (2004)
- "Leishmaniasis: Current status of vaccine development", 14, pp.229~243 (2001)
- "Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study", 3, pp.1447~1456 (2003)
- "Thalidomide stimulates splenic antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice.", 165, pp.237~244 (2000)
- "The levels and patterns of cytokines produced by CD4 T lymphocytes of BALB", c mice infected with Leishmania majorby inoculation into the ear dermis depend on the infectiousness and size of the inoculum, 2003, pp.71, 2674~2683
- "Thalidomide as an emerging immuno-therapeutic agent Immunol Today 60", 44(1), pp.55~61 (1999)
- "Treatment of visceral leishmaniasis a decade of progress and future approaches", 4, pp.158~177 (2000)
- "Clinical and experimental advances intreatment of visceral leishmaniasis", 45, pp.2185~2197 (2001)
- "Role of endogenous gamma interferon and macrophage microbicidal mecha-nisms in host response to chemotherapy in experimental visceral leishmaniasis.", 68, pp.288~293 (2000)
- "Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment", 68, pp.6289~6293 (2000)
- "The relative contribution of IL-4 receptor signal-ing and IL-10 to susceptibility to Leishmania major", 170, pp.5152~5158 (2003)
- "American cutaneous leish-maniasis: use of a skin test as a predictor of relapse after treatment.", 78, pp.968~974 (2000)
- "Analysis of cytokine patterns produced by individual CD4+ lymph node cells during experimental murine leishmaniasis in resis-tant and susceptible mice", 10, pp.1853~1861 (1998)
- "Reactivation of latent leishmaniasis by inhibi-tion of inducible nitric oxide synthase.", 183, pp.1501~1514 (1996)
- "Response to interferon-gamma plus antimony in Indian visceral leishmaniasis.", 176, pp.1117~1119 (1997)
